Cargando…
Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature
Atypical hemolytic uremic syndrome (aHUS) patients treated with eculizumab may require higher doses to achieve and maintain optimal clinical response. Further studies are warranted to elucidate optimal dosing regimens of eculizumab in aHUS patients, and whether dosing regimens can be predicted based...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974426/ https://www.ncbi.nlm.nih.gov/pubmed/27525082 http://dx.doi.org/10.1002/ccr3.628 |
_version_ | 1782446540635242496 |
---|---|
author | Thomson, Nick Ulrickson, Matthew |
author_facet | Thomson, Nick Ulrickson, Matthew |
author_sort | Thomson, Nick |
collection | PubMed |
description | Atypical hemolytic uremic syndrome (aHUS) patients treated with eculizumab may require higher doses to achieve and maintain optimal clinical response. Further studies are warranted to elucidate optimal dosing regimens of eculizumab in aHUS patients, and whether dosing regimens can be predicted based on mutational status, eculizumab levels, or other testing. |
format | Online Article Text |
id | pubmed-4974426 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-49744262016-08-12 Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature Thomson, Nick Ulrickson, Matthew Clin Case Rep Case Reports Atypical hemolytic uremic syndrome (aHUS) patients treated with eculizumab may require higher doses to achieve and maintain optimal clinical response. Further studies are warranted to elucidate optimal dosing regimens of eculizumab in aHUS patients, and whether dosing regimens can be predicted based on mutational status, eculizumab levels, or other testing. John Wiley and Sons Inc. 2016-07-06 /pmc/articles/PMC4974426/ /pubmed/27525082 http://dx.doi.org/10.1002/ccr3.628 Text en © 2016 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Reports Thomson, Nick Ulrickson, Matthew Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature |
title | Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature |
title_full | Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature |
title_fullStr | Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature |
title_full_unstemmed | Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature |
title_short | Maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature |
title_sort | maintenance eculizumab dose adjustment in the treatment of atypical hemolytic uremic syndrome: a case report and review of the literature |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974426/ https://www.ncbi.nlm.nih.gov/pubmed/27525082 http://dx.doi.org/10.1002/ccr3.628 |
work_keys_str_mv | AT thomsonnick maintenanceeculizumabdoseadjustmentinthetreatmentofatypicalhemolyticuremicsyndromeacasereportandreviewoftheliterature AT ulricksonmatthew maintenanceeculizumabdoseadjustmentinthetreatmentofatypicalhemolyticuremicsyndromeacasereportandreviewoftheliterature |